0000000000492583

AUTHOR

J Patel

showing 2 related works from this author

Death following pulmonary complications of surgery before and during the SARS-CoV-2 pandemic

2021

Association of Surgeons in Training Surgical Summit, online, 17 Oct 2020 - 17 Oct 2020 2021 Virtual Annual Meeting / Surgical Research Society, online, 24 Mar 2021 - 25 Mar 2021, National Research Collaborative Meeting, online, 10 Dec 2020 - 10 Dec 2020, Royal Australasian College of Surgeons Annual Academic Surgery Conference, online, 5 Nov 2020 - 5 Nov 2020; The British journal of surgery : BJS 108(12), 1448-1464 (2021). doi:10.1093/bjs/znab336

MaleRespiration Artificial/statistics & numerical dataSettore MED/18 - CHIRURGIA GENERALEeducation-Sciences du Vivant [q-bio]/Médecine humaine et pathologieAbdominal NeoplasmPostoperative Complications/mortalityNOsurgeryCohort Studies03 medical and health sciencesCOVID-19; death; SARS-CoV-2; surgery0302 clinical medicinePostoperative ComplicationsdeathHumans030212 general & internal medicinePandemicsAbdominal Neoplasms/surgeryAgedLS7_4COVID-19/mortalityRespiratory Distress SyndromePandemicSARS-CoV-2Respirationsurgical procedures operativemortalitysurgery specialtypandemicspulmonary complicationssars-cov-2covid-19coronavirus pandemicCOVID-19Middle Aged3126 Surgery anesthesiology intensive care radiologyRespiration Artificialsurgical proceduresoperativemortalitysurgery specialtypandemicspulmonary complicationssars-cov-2covid-19coronavirus pandemicAbdominal Neoplasms; Aged; COVID-19; Cohort Studies; Female; Humans; Male; Middle Aged; Pandemics; Postoperative Complications; Respiration Artificial; Respiratory Distress Syndrome; Elective Surgical ProceduresElective Surgical Procedures030220 oncology & carcinogenesisAbdominal NeoplasmsArtificialFemalePostoperative ComplicationCohort Studie[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyRespiratory Distress Syndrome/mortalityHuman
researchProduct

Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism

2013

BackgroundWhether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous thromboembolism is unclear. MethodsIn a randomized, double-blind, noninferiority study, we randomly assigned patients with acute venous thromboembolism, who had initially received heparin, to receive edoxaban at a dose of 60 mg once daily, or 30 mg once daily (e.g., in the case of patients with creatinine clearance of 30 to 50 ml per minute or a body weight below 60 kg), or to receive warfarin. Patients received the study drug for 3 to 12 months. The primary efficacy outcome was recurrent symptomatic venous thromboembolism. The principal safety outcome was major or clinically re…

MESH: Pulmonary EmbolismMale[SDV]Life Sciences [q-bio]Kaplan-Meier Estimate030204 cardiovascular system & hematologylaw.inventionMESH: Venous Thromboembolismchemistry.chemical_compound0302 clinical medicineRandomized controlled trialEdoxabanlawMESH: Double-Blind Method030212 general & internal medicineMESH: WarfarinMESH: AgedMESH: Middle AgedHazard ratioGeneral MedicineVenous ThromboembolismMiddle AgedThrombosis3. Good healthPulmonary embolismAnesthesiaFemaleAnticoagulants EdoxabanMESH: HemorrhageAndexanet alfamedicine.drugMESH: EnoxaparinHemorrhageMESH: AnticoagulantsMESH: Drug Administration ScheduleDrug Administration Schedule03 medical and health sciencesDouble-Blind MethodAged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pulmonary Embolism; Venous Thromboembolism; WarfarinmedicineHumansEnoxaparinAdverse effectMESH: Kaplan-Meier EstimateAgedMESH: Humansbusiness.industryWarfarinAnticoagulantsmedicine.diseaseMESH: MalechemistryWarfarinbusinessPulmonary EmbolismMESH: FemaleNew England Journal of Medicine
researchProduct